

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rojas et al. Examiner: Unassigned  
Serial No.: 10/634,645 Group Art Unit: 1645  
Filed: August 5, 2003 Docket No.: 14507-44063  
Title: Fusion Proteins with a Membrane Translocating Sequence and Methods  
of Using Same to Inhibit an Immune Response

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 18, 2004.

By: \_\_\_\_\_  
Name: Tim Tingkang Xia

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

We are transmitting herewith the attached:

- Transmittal Sheet containing Certificate of Mailing
- Request for Corrected Filing Receipt (2 pages)
- Copy of Filing Receipt Showing Corrections (2 pages)
- Return postcard

MORRIS, MANNING & MARTIN, LLP  
1600 Atlanta Financial Center  
3343 Peachtree Road NE  
Atlanta, Georgia 30326  
404.495.3678  
Customer No. 24728

By: \_\_\_\_\_

Name: Tim Tingkang Xia

Reg. No.: 45,242

TX



10/634,645


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Rojas et al.	Examiner:	Unassigned
Serial No.:	10/634,645	Group Art Unit:	1645
Filed:	August 5, 2003	Docket No.:	14507-44063
Title:	Fusion Proteins with a Membrane Translocating Sequence and Methods of Using Same to Inhibit an Immune Response		

**CERTIFICATE UNDER 37 CFR 1.8:**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 18, 2004.

By:   
Name: Tim Tingkang Xia

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a photocopy of the filing receipt from the United States Patent and Trademark Office in the above-identified application showing requested corrections. The filing receipt is erroneous with respect to the title of the invention. Please delete the second "an" from the title of the invention shown on the filing receipt.

The title of the invention should appear as follows:

**"FUSION PROTEINS WITH A MEMBRANE TRANSLOCATING SEQUENCE  
AND METHODS OF USING SAME TO INHIBIT AN IMMUNE RESPONSE"**

Correction of the records of the United States Patent and Trademark Office and issuance  
of a corrected filing receipt are respectfully solicited.

Respectfully submitted,

MORRIS, MANNING & MARTIN, LLP

  
\_\_\_\_\_  
Tim Tingkang Xia  
Reg. No. 45,242  
TTX

Date: March 18, 2004

1600 Atlanta Financial Center  
3343 Peachtree Road, N.E.  
Atlanta, Georgia 30326-1044  
Phone: 404-233-7000  
Direct: 404-495-3678



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/634,645	08/05/2003	1645	0.00	60068.0002US01	7	88	6

## CONFIRMATION NO. 7190

23552  
MERCHANT & GOULD PC *JMB*  
P.O. BOX 2903  
MINNEAPOLIS, MN 55402-0903

## FILING RECEIPT



\*OC000000011205059\*

Date Mailed: 11/06/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Mauricio Rojas, Atlanta, GA;  
Ana L. Mora, Atlanta, GA;

## Domestic Priority data as claimed by applicant

## Foreign Applications

If Required, Foreign Filing License Granted: 11/06/2003

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No


Early Publication Request: No

\*\* SMALL ENTITY \*\*

## Title

Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response

## Preliminary Class



---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).